Key Points
- Insider Barry Ticho sold 3,662 shares on Dec. 5 at an average price of $31.34 for $114,767, part of a string of recent sales that reduced his stake by 15.61% to 19,798 shares valued at about $620,469.
- Stoke reported Q results of ($0.65) EPS (missed by $0.11) but revenue of $10.63M topped expectations; the stock traded around $30.87 with a 50‑day SMA of $29.03, 200‑day SMA of $19.83, a market cap near $1.76B and a 52‑week range of $5.35–$38.69.
- Analysts have been raising targets and ratings recently, leaving a consensus 'Buy' rating with an average price target of $31.00.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 1,018 shares of the company's stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $30.87, for a total transaction of $31,425.66. Following the sale, the general counsel directly owned 24,594 shares of the company's stock, valued at approximately $759,216.78. This trade represents a 3.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Jonathan Allan also recently made the following trade(s):
- On Friday, December 5th, Jonathan Allan sold 8,785 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.29, for a total transaction of $274,882.65.
- On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total value of $70,249.80.
- On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total value of $68,017.52.
- On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.07, for a total value of $250,700.00.
Stoke Therapeutics Stock Performance
Stoke Therapeutics stock opened at $30.87 on Friday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The stock has a market capitalization of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14. The stock has a fifty day moving average of $29.03 and a 200-day moving average of $19.83.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. On average, research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on STOK. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stoke Therapeutics in a report on Monday. Canaccord Genuity Group raised their target price on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. upped their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a "neutral" rating in a report on Monday, November 3rd. Needham & Company LLC increased their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, October 10th. Finally, Chardan Capital upgraded Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $31.00.
View Our Latest Stock Report on Stoke Therapeutics
Institutional Investors Weigh In On Stoke Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in STOK. Generali Investments Management Co LLC bought a new position in shares of Stoke Therapeutics in the third quarter valued at approximately $41,000. BNP Paribas Financial Markets lifted its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after acquiring an additional 1,668 shares during the period. Tower Research Capital LLC TRC boosted its position in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after purchasing an additional 3,591 shares during the last quarter. AlphaQuest LLC purchased a new position in Stoke Therapeutics in the first quarter worth $72,000. Finally, US Bancorp DE grew its stake in Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after purchasing an additional 11,108 shares during the period.
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
